加拿大多伦多大学吴教授学术报告

报告题目：Advances in the Design of Nanomedicine for Enhancing Cancer Therapies

报告人：Professor Xiao Yu (Shirley) Wu

FAAPS Director of Advanced Pharmaceutics & Drug Delivery Laboratory, Leslie Dan Faculty of Faculty of Pharmacy, University of Toronto, Ontario, Canada

主持人：陈永明  教授

时间：2017年11月16日（星期四）下午15：30

地点：丰盛堂芙兰学术交流中心A402

欢迎广大师生参加！

摘要：

Chemotherapy is a main treatment of malignant tumors and metastatic cancer.  However, drug resistance of cancer cells and drug-induced normal tissue toxicity limit the success of the treatment. Drug resistance is multifactorial involving numerous molecular, cellular, and non-cellular mechanisms. Similarly radiation therapy, a major therapy received by over 50% of cancer patients, encounters tremendous tumor resistance due to hypoxic tumor microenvironment (TME) and hypoxia-induced factors. To tackle multifaceted resistance mechanisms, Dr. Wu’s group has designed various novel nanoparticle systems by exploiting tumor selective bioreactivity of nanomaterials, intracellular synergistic drug-drug interactions and bioreactions of nanomaterial and drugs. These nanoparticle formulations significantly enhanced efficacy against multidrug resistant cancer cells while dramatically reducing systemic toxicity in preclinical tumor models. Her laboratory has devised and applied for the first time pharmaceutically acceptable hybrid manganese dioxide nanoparticles and demonstrated their selective activity to modulate TME and overcome hypoxia-induced resistance to radiotherapy. In this presentation, Dr. Wu will provide an overview of the design concepts, underlying bioreaction mechanisms, and the therapeutic benefits of these nanomedicine systems.